Canakinumab administered as monotherapy has also recently been shown to be efficacious in refractory BD, confirming that inhibition of the proinflammatory effects of IL-1β is paramount in controlling the clinical spectrum of BD [50]. This evidence concerns the gene IL1B and Behcet disease.